Addendum: Systemic AL amyloidosis: current approach and future direction
Metrics: PDF 200 views | ?
1Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY 13210, USA
2University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA
4Department of Medicine and Medical Sciences, University of Balamand, Balamand, Lebanon
5Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
6Department of Internal Medicine, UnityPoint Methodist, Peoria, IL 61636, USA
7Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ 07740, USA
8Hematology and Medical Oncology, Houston Methodist Cancer Center, Houston, TX 77094, USA
9Department of Hematology-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
10Department of Hematology-Oncology, Myeloma and Amyloidosis Program, Maroone Cancer Center, Cleveland Clinic Florida, Weston, FL 33331, USA
Published: July 20, 2023
Copyright: © 2023 Bou Zerdan et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article has an addendum: Research funding was obtained from the Cleveland Clinic Florida, Maroone Cancer Center, Malignant Hematology Research Fund.
Original article: Oncotarget. 2023; 14:384-394. DOI: https://doi.org/10.18632/oncotarget.28415.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.